Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
CYP1A1 0.23 μM (Ki)
|
---|---|
ln Vitro |
The half-lives (t1/2) of compound ten, Antitumor agent-87, in rat, mouse, and human liver microsomes are 107, 44, and 70 minutes, respectively [1]. Cell cycle arrest in the G2/M phase is induced by antitumor agent-87 (1250 nM) [1]. HT-1080CYP1A1, HT-1080empty, HT-1080, MDA-MB-231, MDA-MB-468, T47D, and SK-BR-3 are among the proliferative organisms that antitumor agent-87 (0-12500 nM; 72 h) exhibits antiproliferative action against. The IC50 values of MCF7 cells are 500, 8800, 6800, >12500, 210, 1100, 79, and 43 nM, respectively[1].
|
ln Vivo |
In chicken embryos, anticancer agent-87 (0.1 µg/egg) shows antitumor action[1].
|
Cell Assay |
Cell Proliferation Assay[1]
Cell Types: MCF7, HT-29, M21 cells Tested Concentrations: 0-12500 nM Incubation Duration: 48 h Experimental Results: demonstrated antiproliferative activity with IC50s of 600, >12500, >12500 nM for MCF7, HT-29 , M21 cells, respectively. Cell Cycle Analysis[1] Cell Types: MCF7 cells Tested Concentrations: 1250 nM Incubation Duration: Experimental Results: Induced the accumulation of the cells in the G2/M phase of 57% and induced disruptions of the cytoskeleton of MCF7 cells . |
Animal Protocol |
Animal/Disease Models: chick embryos (HT-1080CYP1A1, HT-1080empty, HT-1080 cells)[1]
Doses: 0.1 µg/egg Route of Administration: Experimental Results: Did not show statistically significant antitumor activity on grafted cell lines devoid of CYP1A1 (HT-1080 and HT-1080empty), demonstrated antitumoral inhibition of 29% on the grafted HT-1080CYP1A1. |
References |
[1]. Chavez Alvarez AC, et al. Homologation of the Alkyl Side Chain of Antimitotic Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonate Prodrugs Selectively Targeting CYP1A1-Expressing Breast Cancers Improves Their Stability in Rodent Liver Microsomes. J Med Chem. 2023 Feb 23;66(4):2477-2497.
|
Molecular Formula |
C22H28N2O6S
|
---|---|
Molecular Weight |
448.53
|
CAS # |
1422527-88-5
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C1(S(OC2=CC(OC)=CC(OC)=C2)(=O)=O)=CC=C(N2C(=O)N(CCCCC)CC2)C=C1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2295 mL | 11.1475 mL | 22.2951 mL | |
5 mM | 0.4459 mL | 2.2295 mL | 4.4590 mL | |
10 mM | 0.2230 mL | 1.1148 mL | 2.2295 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.